Moreover, the 2′-O-MOE-PS-modified mt21 ASO-4 and mt29 ASO-4 can inhibit the expression of full-length PD-L1 induced by IFN-γ, providing new approaches to compromise the side effects of IFN-γ-related anti-tumor therapy. The gene discussed is IFNG; the disease is neoplasm.